US FDA Needs ‘More Streamlined’ REMS Enforcement Authority, Inspector General Says
Executive Summary
Additional power would allow the agency to punish 'simple' REMS violations and improve administration of risk management programs, according to a new report looking at FDA's oversight of opioids.